Komori
Business Alliances3750ADR Biomedical Holdings Inc.Electrical Equipment & Precision Instruments

(Update on disclosed matter) Notice regarding the commencement of a clinical trial (confirmatory study) of an ADRC-based treatment for critical limb ischemia

The Company's subsidiary resolved to commence a confirmatory study of an ADRC-based treatment for critical limb ischemia, with the aim of commercializing the treatment and obtaining insurance coverage. The PMDA consultation has concluded, and the study protocol has been largely finalized.

Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

3750ADR Biomedical Holdings Inc.
Alliance partnerNagoya University
Impact on Business Performance

Currently under review. The Company will promptly announce any matters that arise requiring disclosure.

Date of board resolution28 October 2026Contract Date21 May 2025
Agreements reached under this partnership
ItemDetails
Name of alliance partnerNagoya University
Date of board resolution28 October 2026
Contract Date21 May 2025
Impact on Business PerformanceCurrently under review. The Company will promptly announce any matters that arise requiring disclosure.
Items this document does not state (19)
Alliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To commercialize the treatment and obtain insurance coverage.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Update on disclosed matter) Notice regarding the commencement of a clinical trial (confirmatory study) of an ADRC-based treatment for critical limb ischemia | ADR Biomedical Holdings Inc. (3750) timely disclosure | Komori